Latest News
PTC Therapeutics, Inc.
- PTC Therapeutics, Inc. Estimates – DUS:BH3
- PTC Therapeutics director sells $149,036 in shares
- Form 4 PTC Therapeutics Inc: Michael Schmertzler (Director) For: 14 October
- PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026
- Ptc Therapeutics stock hits 52-week low at $61.20 By Investing.com
- PTC Therapeutics CLO Mark Boulding sells $12,337 in stock
- PTC Therapeutics director Glenn Steele sells $781,920 in shares
- PTC Therapeutics director Michael Schmertzler sells $158k in shares By Investing.com
- PTC Therapeutics (PTCT) Gets a Hold from RBC Capital
- PTC Therapeutics (PTCT) Edges Lower to $63.23 as Traders Eye Range Boundaries - Hot Stock Picks
- PTC Therapeutics CLO Mark Boulding sells $132,790 in shares
- PTC Therapeutics Jumps 5.5% Amid Sector-Wide Rally
Headlines from the last 30 days, linking to the original publishers. See all market news →